It has been accepted since the 1990s that palliative chemotherapy can significantly prolong the survival of patients with advanced gastric carcinoma, compared to supportive care alone [1, 2] . However, there is controversy over the benef it of salvage therapy past second-line due to the lack of evidence. Recently, there has been renewed interest in salvage chemotherapy after first-and second-line treatments have failed because of the prolonged survival time and relatively low toxicity of agents.
Many clinicians consider secondline chemotherapy after failure of first-line chemotherapy for patients w ith advanced gastric carcinoma [3] . Phase II trials and retrospective analyses have provided evidence that second-line is effective [4] . Recently, randomized phase III trials have strongly indicated that second line or further chemotherapy is more advantageous than supportive care (Table  1) . A German trial found that irinotecan monotherapy improved overall survival compared to best supportive care [5] . A Korean trial found that irinotecan or docetaxel monotherapy prolonged overall survival compared to best supportive care and there was no difference in the treatment effect of docetaxel and irinotecan (p = 0.116) [6] . In the 2013 the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, it was reported that docetaxel [7] and ramucirumab [8] demonstrated clinical benef it over supportive care in two phase III trials. Both agents significantly prolonged overall survival (Table 1 ). There is ample evidence to support the use of second line treatment in advanced gastric cancer. However, the issue of which regimen is a standard second-line treatment has not been clarified.
Little information concerning the survival advantage of third-line chemotherapy is extant. In a Korean phase III trial, the survival benefit in the chemotherapy arm was preserved in the further chemotherapy group (hazard ratio, 0.812; 95% confidence interval [CI], 0.450 to 1.464) ( Table 1) . Several retrospective studies presented the natural history of advanced gastric cancer with sequential salvage chemotherapy following f irst-line treatment [4] . The survival prolongation by second-and third-line salvage chemotherapy indicates its feasibility in selected patients.
After failure of first-line chemotherapy based on platinum and fluoropyrimidine, irinotecan, or taxane-based regimens have benef ited survival and led to the same clinical outcome
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as salvage chemotherapy in advanced gastric cancer patients [4, 6] . Based on the lack of cross-resistance between irinotecan and taxane, both regimens are plausible salvage treatment options. Additionally, it is necessary to select patients for salvage chemotherapy based on survival predictors including performance status, chemotherapy-free interval, response duration, metastatic pattern, tumor burden, and serum carcinoembryonic antigen level [4, 6] .
Lee and colleagues [9] evaluated the eff icacy and toxicity of docetaxel monotherapy, 75 mg/m 2 on day 1 every 3 weeks, in advanced gastric cancer patients who did not respond to oxaliplatin with leucovorin and 5-f luorouracil (m-FOLFOX-4), or to irinotecan with leucovorin and 5-fluorouracil (m-FOLFIRI). This retrospective study included thirty three patients and reported an overall response of 15%, time to progression of 2.1 months (95% CI, 1.63 to 2.58), and an overall survival time of 4.7 months (95% CI, 3.20 to 6.20). The results are comparable to previous reports of the efficacy of third-line treatment. This study provides important evidence that docetaxel is a feasible third-line therapy regimen after m-FOLFIRI and m-FOLFOX-4 regimens. A randomized prospective trial could further support this conclusion. Trastuzumab, a molecular target agent, was approved for HER2 amplif ied gastric cancer patients, and other anti-HER2 agents-including lapatinibhave been evaluated as f irst-or second-line treatments. Furthermore, studies have been performed to elucidate biomarkers of chemotherapeutic agents and to investigate molecular biological features, including genetic and epigenetic profiles [10] . On the basis of those outcomes, randomized trials of target agents, and molecular biologic markers would facilitate treatment tailored to the individual patient.
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